Histogenics raises $34 million after ProChon Biotech merger

May 27, 2011 by MassDevice staff

Histogenics, which merged with ProChon Biotech last week, reels in $34 million in equity and debt funding as part of the deal.

Histogenics, ProChon Biotech

Histogenics Corp. brought in more than $34 million in equity and debt financing after its acquisition of fellow Bay State firm ProChon Biotech Ltd.

The two companies merged in an all-stock deal that brings ProChon CEO Patrick O'Donnell into the Histogenics corner office.

O'Donnell told MassDevice.com last week that a deal has been in the works since the early part of 2011.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.